TB TREATMENTS: RI-ALTA STUDY
Dried Blood Spot Sampling to Assess Rifampicin Exposure and Treatment Outcomes among Native and Non-Native Tuberculosis Patients in Paraguay: An Exploratory Study
Ten of our consortium collegaues collaborated on the publication of this article in Pharmaceutics. Samiksha Ghimire, Gladys Molinas, Arturo Battaglia, Nilza Martinez, Luis Gómez Paciello,
Sarita Aguirre, Jan-Willem C. Alffenaar, Marieke Sturkenboom and Cecile Magis-Escurra, thank you for the amazing work!
Tuberculosis treatment with optimized dose rifampicin
The aim of the World Health Organization (WHO) "End TB Strategy" is to end the global pandemic by 2035. If we want to achieve that, we need better treatments. Treatments that are more effective and that might shorten the treatment duration.
This study researches the safety and tolerability of a higher-than-standard dose of the antibiotic rifampicin in TB treatment. Previous studies have already found that treating with an optimized dose of this antibiotic is safe and shows potential to shorten TB treatment duration. However, in these studies, the patients beloning to the difficult to treat patient subgroups were underrepresented. This research will have these patients as a study population.
For a period of 8 weeks, TB-patients with certain types of co-morbidities and elderly TB-patients are treated with an optimized dosage of 35 milligram rifampicine per kilogram body weight. After that, they will be treated with the standard dosages. Patients will be followed-up for 12 months.
The participating sites in this study are:
Radboud UMC, Nijmegen, the Netherlands
UMCG, Groningen, the Netherlands
Vall d'Hebron University Hospital, Barcelona, Spain
UHC São João, Porto, Portugal
INERAM, Asunción, Paraguay
For more information, see the registration of this trial in clinicaltrials.gov by clicking here.